Last reviewed · How we verify
Aripiprazole, OPC-14597
At a glance
| Generic name | Aripiprazole, OPC-14597 |
|---|---|
| Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Substance Misuse To Psychosis for Stimulants (PHASE2, PHASE3)
- Cerebellum-based Imaging Neural Markers for Antipsychotic Response
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole (PHASE4)
- Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. (PHASE4)
- C-Cog in Early Course Schizophrenia Study (PHASE4)
- Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia (PHASE3)
- Enhancing Recovery in Early Schizophrenia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: